These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17342116)

  • 21. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
    Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy: friend or foe to cancer vaccines?
    Emens LA; Machiels JP; Reilly RT; Jaffee EM
    Curr Opin Mol Ther; 2001 Feb; 3(1):77-84. PubMed ID: 11249735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine.
    Huang X; Ye D; Thorpe PE
    Vaccine; 2011 Jun; 29(29-30):4785-93. PubMed ID: 21557977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
    Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
    Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
    Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
    Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
    Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
    Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis.
    Zhou Q; Gault RA; Kozel TR; Murphy WJ
    Infect Immun; 2006 Apr; 74(4):2161-8. PubMed ID: 16552046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coadministration of interleukins 7 and 15 with bacille Calmette-Guérin mounts enduring T cell memory response against Mycobacterium tuberculosis.
    Singh V; Gowthaman U; Jain S; Parihar P; Banskar S; Gupta P; Gupta UD; Agrewala JN
    J Infect Dis; 2010 Aug; 202(3):480-9. PubMed ID: 20569158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A study of immune surveillance for bladder tumor. II. Immunoresponse of tissue infiltrating lymphocytes following immunomodulator injection in bladder tumors].
    Tsujihashi H; Matsude H; Akiyama T; Kurita T; Uejima S
    Nihon Hinyokika Gakkai Zasshi; 1988 Jan; 79(1):115-21. PubMed ID: 3260977
    [No Abstract]   [Full Text] [Related]  

  • 31. Mutual enhancement of IL-2 and IL-7 on DNA vaccine immunogenicity mainly involves regulations on their receptor expression and receptor-expressing lymphocyte generation.
    Zhang Y; Liang S; Li X; Wang L; Zhang J; Xu J; Huo S; Cao X; Zhong Z; Zhong F
    Vaccine; 2015 Jul; 33(30):3480-7. PubMed ID: 26055295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination.
    Xu H; Zhao G; Huang X; Ding Z; Wang J; Wang X; Cheng Y; Kang Y; Wang B
    J Gene Med; 2010 Jan; 12(1):97-106. PubMed ID: 19950201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Novel adjuvants in vaccine development].
    Kaufmann AM; Schmidt-Ott R; Prechtl A
    MMW Fortschr Med; 2011 Jan; 153(1-2):44. PubMed ID: 24761492
    [No Abstract]   [Full Text] [Related]  

  • 34. Antigen/adjuvant-carrying nanoparticles show promise for vaccine delivery.
    Immunotherapy; 2011 Apr; 3(4):467. PubMed ID: 21463186
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
    van Dissel JT; Joosten SA; Hoff ST; Soonawala D; Prins C; Hokey DA; O'Dee DM; Graves A; Thierry-Carstensen B; Andreasen LV; Ruhwald M; de Visser AW; Agger EM; Ottenhoff TH; Kromann I; Andersen P
    Vaccine; 2014 Dec; 32(52):7098-107. PubMed ID: 25454872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice.
    Arama C; Waseem S; Fernández C; Assefaw-Redda Y; You L; Rodriguez A; Radošević K; Goudsmit J; Kaufmann SH; Reece ST; Troye-Blomberg M
    Vaccine; 2012 Aug; 30(37):5578-84. PubMed ID: 21983157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key.
    Bachmann MF; Hunziker L; Zinkernagel RM; Storni T; Kopf M
    Eur J Immunol; 2004 Feb; 34(2):317-26. PubMed ID: 14768036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.
    Hernández AM; Vázquez AM
    Expert Rev Vaccines; 2015 Jan; 14(1):9-20. PubMed ID: 25420897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of IFN-gamma on CD40-mediated activation of B cells from X-linked immunodeficient or normal mice.
    Johnson-Léger C; Hasbold J; Holman M; Klaus GG
    J Immunol; 1997 Aug; 159(3):1150-9. PubMed ID: 9233608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.